Delgocitinib Synthesis Route Patent Information
Information regarding patents specifically covering the synthesis route of delgocitinib is not readily available in the provided context. Patent databases would need to be consulted for detailed information on these specific intellectual property rights.
What is Delgocitinib Used For?
Delgocitinib is a topical Janus kinase (JAK) inhibitor that has been developed for the treatment of atopic dermatitis [1]. It works by suppressing the immune response that contributes to the inflammation and itching associated with this skin condition [1].
When Does Delgocitinib's Exclusivity Expire?
Specific patent expiry dates for delgocitinib, including those that might cover its synthesis route, are not detailed in the provided information. DrugPatentWatch.com [2] is a resource that tracks drug patents and exclusivity periods, which could be consulted for more precise information on delgocitinib's patent landscape.
How Does Delgocitinib Compare to Other Atopic Dermatitis Treatments?
Delgocitinib represents a novel approach to treating atopic dermatitis as a topical JAK inhibitor [1]. Traditional treatments for atopic dermatitis include topical corticosteroids and calcineurin inhibitors, which aim to reduce inflammation. However, delgocitinib's mechanism of action, targeting specific signaling pathways involved in the immune response, offers a different therapeutic strategy [1].
What are the Clinical Trial Results for Delgocitinib?
Clinical trials have evaluated delgocitinib's efficacy and safety in patients with atopic dermatitis. These studies have generally shown that delgocitinib can lead to significant improvements in skin lesion severity and pruritus (itching) [1]. Further details on specific trial outcomes would typically be found in published clinical study reports and regulatory submissions.
Are There Any Concerns About Delgocitinib Side Effects?
As with any medication, delgocitinib can have side effects. Common side effects reported in clinical studies include application site reactions, such as eczema, dermatitis, and pruritus at the application site [1]. Systemic side effects associated with JAK inhibitors, such as increased risk of infections, cardiovascular events, and malignancy, are also a consideration, though topical application may limit systemic exposure compared to oral JAK inhibitors [1].
Who Manufactures Delgocitinib?
Torii Pharmaceutical Co., Ltd. developed delgocitinib [1].
Sources
[1] https://www.drugpatentwatch.com/p/delgocitinib/42521
[2] https://www.drugpatentwatch.com/